Dueling Reviews for Controversial Flu Drug

摘要

Were the billions of dollars that governments spent on the antiviral drug Tamiflu to protect their populations from a flu pandemic a waste of money? For years now, an international group of researchers has said the answe r may well be yes. Working under the umbrella of the Cochrane Collaboration, a global network of scientists reviewing medical evidence, the group says it's not clear that Tamiflu (also known as oselta-mivir) can prevent complications from influenza or keep people out of the hospital. It has also waged a vigorous campaign calling on Roche, Tamiflu's manufacturer, to make public a series of unpublished trials on the drug.